About Seres Therapeutics
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI, SER-287 to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens. The Company is also conducting research on metabolic diseases, such as early-stage, non-insulin dependent diabetes; obesity and metabolic syndrome; other inflammatory diseases; cancer chemotherapy and immune suppression, and rare genetic diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: MCRB
- Previous Close: $9.19
- 50 Day Moving Average: $10.04
- 200 Day Moving Average: $10.85
- 52-Week Range: $8.05 - $35.98
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.34
- P/E Growth: -0.08
- Market Cap: $370.86M
- Outstanding Shares: 40,355,000
- Beta: 0.3
- Return on Equity: -47.97%
- Return on Assets: -30.02%
Companies Related to Seres Therapeutics:
- Debt-to-Equity Ratio: 0.07%
- Current Ratio: 6.54%
- Quick Ratio: 6.54%
What is Seres Therapeutics' stock symbol?
Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."
Where is Seres Therapeutics' stock going? Where will Seres Therapeutics' stock price be in 2017?
8 equities research analysts have issued 12-month target prices for Seres Therapeutics' shares. Their forecasts range from $12.00 to $50.00. On average, they expect Seres Therapeutics' stock price to reach $26.17 in the next twelve months.
When will Seres Therapeutics announce their earnings?
Seres Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.
What are analysts saying about Seres Therapeutics stock?
Here are some recent quotes from research analysts about Seres Therapeutics stock:
According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (2/2/2017)
Cowen and Company analysts commented, "MCRB released root cause analysis findings from the SER-109 failed Ph2 and in-." (2/1/2017)
Canaccord Genuity analysts commented, "We believe that SER-109 Phase 2 trial study power was decreased by the inclusion of misdiagnosed and non-disease active patients. MCRB indicated that 72 of the 89 patients enrolled in the Phase 2 trials were chosen based on C. Difficile PCR diagnosis. A positive PCR test indicates that the cytotoxin gene is present, but does not directly indicate that the C. Difficile bacterium is producing the cytotoxin that causes the underlying symptoms. Thus a direct testing of cytotoxin is the most indicative of disease activity, and further qualifying stool samples analysis showed that only 15 of 31 PCR- positive samples were cytotoxin-positive. Importantly, Optimer utilized toxin testing for its fidaxomicin clinical program for recurrent C." (1/31/2017)
Who owns Seres Therapeutics stock?
Seres Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.99%), Federated Investors Inc. PA (2.76%), Artal Group S.A. (1.73%), ARK Investment Management LLC (1.22%), Renaissance Technologies LLC (0.99%) and State Street Corp (0.68%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis, Roger Pomerantz and Ventures Fund 2007 L Flagship.
Who sold Seres Therapeutics stock? Who is selling Seres Therapeutics stock?
Seres Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA and Tudor Investment Corp Et Al. Company insiders that have sold Seres Therapeutics stock in the last year include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis, Roger Pomerantz and Ventures Fund 2007 L Flagship.
Who bought Seres Therapeutics stock? Who is buying Seres Therapeutics stock?
Seres Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Artal Group S.A., Renaissance Technologies LLC, Oxford Asset Management, State Street Corp, Trexquant Investment LP, FMR LLC and Ellington Management Group LLC.
How do I buy Seres Therapeutics stock?
Shares of Seres Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Seres Therapeutics stock cost?
One share of Seres Therapeutics stock can currently be purchased for approximately $9.19.